Adarx Pharmaceuticals, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2019-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.adarx.com
Clinical Trials
6
Active:0
Completed:0
Trial Phases
3 Phases
Phase 1:3
Phase 2:2
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (6 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (50.0%)Phase 2
2 (33.3%)Phase 3
1 (16.7%)Phase 2 Study of ADX-038 in Participants With Geographic Atrophy
Phase 2
Not yet recruiting
- Conditions
- Geographic Atrophy Secondary to Age-related Macular Degeneration
- Interventions
- Drug: Placebo
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 240
- Registration Number
- NCT06990269
Phase 2 Study of ADX-038 in Complement-Mediated Kidney Disease
Phase 2
Not yet recruiting
- Conditions
- IgANC3GComplement-mediated Kidney Disease
- Interventions
- First Posted Date
- 2025-05-25
- Last Posted Date
- 2025-06-10
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 30
- Registration Number
- NCT06989359
STOP-HAE: A Phase 3 Study of ADX-324 in HAE
- First Posted Date
- 2025-05-07
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT06960213
- Locations
- 🇺🇸
Acuro Research, Inc., Little Rock, Arkansas, United States
Safety, Tolerability, PK and PD of ADX-850 in Participants With Hypertension
Phase 1
Recruiting
- Conditions
- Hypertension,EssentialHypertension
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2025-07-20
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 120
- Registration Number
- NCT06205628
- Locations
- 🇦🇺
Clinitrials Pty Ltd, Perth, Australia
🇦🇺CMAX Clinical Research, Adelaide, South Australia, Australia
🇦🇺Linear Clinical Research, Nedlands, Western Australia, Australia
Safety, Tolerability, PK and PD of ADX-038 in Healthy Participants and Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients
Phase 1
Recruiting
- Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-05-25
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- ADARx Pharmaceuticals, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT05876312
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
🇦🇺Nucleus Network Brisbane, Brisbane, Queensland, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
- Prev
- 1
- 2
- Next
News
No news found